LENZ Therapeutics Inc.’s recent filing unveils that its Chief Financial Officer Chevallard Daniel R. acquired Company’s shares for reported $49988.0 on May 14 ’24. In the deal valued at $15.68 per share,3,188 shares were bought. As a result of this transaction, Chevallard Daniel R. now holds 3,188 shares worth roughly $71379.32.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, MCCOLLUM JAMES W bought 31,332 shares, generating $501,093 in total proceeds. Upon buying the shares at $15.99, the Director now owns 525,565 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. bought 998,009 shares. LENZ Therapeutics Inc. shares valued at $15,000,075 were divested by the Director at a price of $15.03 per share. As a result of the transaction, RA CAPITAL MANAGEMENT, L.P. now holds 3,319,339 shares, worth roughly $74.32 million.
H.C. Wainwright initiated its LENZ Therapeutics Inc. [LENZ] rating to a Buy in a research note published on August 12, 2024; the price target was $38. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in mid April with a ‘”an Outperform”‘ rating. Leerink Partners began covering LENZ with “an Outperform” recommendation on April 15, 2024. Citigroup started covering the stock on April 10, 2024. It rated LENZ as “a Buy”.
Price Performance Review of LENZ
On Friday, LENZ Therapeutics Inc. [NASDAQ:LENZ] saw its stock jump 1.40% to $22.39. Over the last five days, the stock has gained 2.42%. LENZ Therapeutics Inc. shares have risen nearly 80.57% since the year began. Nevertheless, the stocks have risen 97.12% over the past one year. While a 52-week high of $25.77 was reached on 03/11/24, a 52-week low of $9.51 was recorded on 06/04/24. SMA at 50 days reached $22.79, while 200 days put it at $19.75.
Levels Of Support And Resistance For LENZ Stock
The 24-hour chart illustrates a support level at 21.93, which if violated will result in even more drops to 21.47. On the upside, there is a resistance level at 22.64. A further resistance level may holdings at 22.89. The Relative Strength Index (RSI) on the 14-day chart is 50.42, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.50, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.70%. Stochastics %K at 36.35% indicates the stock is a holding.
How much short interest is there in LENZ Therapeutics Inc.?
A steep rise in short interest was recorded in LENZ Therapeutics Inc. stocks on 2024-08-30, growing by 0.17 million shares to a total of 2.1 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-31 was 1.93 million shares. There was a rise of 8.17%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 27, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $28 price target.